These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 21166558

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Review of contemporary antiarrhythmic drug therapy for maintenance of sinus rhythm in atrial fibrillation.
    Singla S, Karam P, Deshmukh AJ, Mehta J, Paydak H.
    J Cardiovasc Pharmacol Ther; 2012 Mar; 17(1):12-20. PubMed ID: 21335483
    [Abstract] [Full Text] [Related]

  • 23. Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation.
    Duray GZ, Ehrlich JR, Hohnloser SH.
    Curr Opin Cardiol; 2010 Jan; 25(1):53-8. PubMed ID: 19881340
    [Abstract] [Full Text] [Related]

  • 24. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN.
    Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
    [Abstract] [Full Text] [Related]

  • 25. Dronedarone: an overview.
    Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M.
    Ann Med; 2012 Feb; 44(1):60-72. PubMed ID: 21745093
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. New antiarrhythmic agents for atrial fibrillation and atrial flutter.
    Pecini R, Elming H, Pedersen OD, Torp-Pedersen C.
    Expert Opin Emerg Drugs; 2005 May; 10(2):311-22. PubMed ID: 15934869
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Vernakalant. Too dangerous in atrial fibrillation.
    Prescrire Int; 2012 May; 21(127):119-22. PubMed ID: 22827000
    [Abstract] [Full Text] [Related]

  • 31. Dronedarone: an emerging agent with rhythm- and rate-controlling effects.
    Wegener FT, Ehrlich JR, Hohnloser SH.
    J Cardiovasc Electrophysiol; 2006 Sep; 17 Suppl 2():S17-20. PubMed ID: 16939434
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of dronedarone: a review of randomized trials.
    Christiansen CB, Torp-Pedersen C, Køber L.
    Expert Opin Drug Saf; 2010 Jan; 9(1):189-99. PubMed ID: 20001756
    [Abstract] [Full Text] [Related]

  • 37. Atrial fibrillation and the expanding role of catheter ablation: do antiarrhythmic drugs have a future?
    Naccarelli GV, Gonzalez MD.
    J Cardiovasc Pharmacol; 2008 Sep; 52(3):203-9. PubMed ID: 18806600
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
    Conde D.
    Int J Cardiol; 2013 Oct 30; 169(2):95-6. PubMed ID: 24071384
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.